The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Tumour Immune Analysis in Osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cuprotopsis, a recently identified programmed cell death pathway, involves long noncoding RNAs (lncRNAs) in its regulation.
• The role of cuprotopsis-related lncRNAs in osteosarcoma, a common bone cancer, remains largely unexplored.
• This research investigates the potential of cuprotopsis-related lncRNAs as prognostic biomarkers in osteosarcoma.

Purpose of the Study:

• To develop a prognostic gene signature based on cuprotopsis-related lncRNAs for osteosarcoma patients.
• To evaluate the reliability and clinical utility of the developed risk model.
• To explore potential therapeutic targets and the relationship between the risk score and tumor immunity.

Main Methods:

• Utilized The Cancer Genome Atlas (TCGA) and UCSC Xena database for osteosarcoma gene expression and clinical data.
• Constructed a cuprotopsis-related lncRNA risk model to assess patient prognosis.
• Performed cluster analysis, clinicopathological correlation, functional enrichment, and compound prediction, validated by RT-qPCR.

Main Results:

• Identified nine key lncRNAs (AC124798.1, AC006033.2, AL450344.2, AL512625.2, LINC01060, LINC00837, AC004943.2, AC064836.3, AC100821.2) for the prognostic model.
• The established risk model demonstrated high reliability in predicting osteosarcoma patient outcomes, with higher risk scores correlating to poorer prognosis.
• Functional enrichment analysis indicated associations with cell metabolism and tumor biology; three potential therapeutic compounds were identified.

Conclusions:

• Cuprotopsis-related lncRNAs are significantly associated with osteosarcoma patient prognosis.
• The developed nine-lncRNA signature effectively predicts osteosarcoma prognosis and holds promise for guiding individualized treatment strategies.